Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers identified microRNA-22 as a key player in Ewing's Sarcoma, regulating KDM3A gene expression. Targeting KDM3A with small-molecule inhibitors may provide new therapeutic options for the disease.
A Moffitt Cancer Center study found that consistent HPV vaccine recommendations from family doctors are lacking, contributing to low vaccination rates. The research team recommends more HPV vaccine recommendations by family physicians to increase uptake.
Researchers have found that trastuzumab can improve outcomes for bladder cancer patients with HER2 amplification, a known driver of aggressive tumors. The study identified 15% of MPUC patients had HER2 amplification, leading to faster growth and higher recurrence rates.
Researchers at Columbia University Medical Center found a single mutation in osteoblasts can cause AML in mice and nearly 40% of patients with the disease. The mutation leads to cancer in adjacent bone-marrow stem cells through signaling pathways.
The Damon Runyon-Rachleff Innovation Award funds groundbreaking projects that aim to prevent, diagnose, and treat cancer. This year's recipients are Emily P. Balskus, Arvin C. Dar, Summer L. Gibbs, Xiaolin Nan, Moritz F. Kircher, and Eirini Papapetrou, who will receive $450,000 over three years for their innovative ideas.
A multinational project led by Dr. Tyler Curiel aims to develop an antibody that can block a specific cancer metabolic pathway and reduce its ability to suppress the immune system.
A new analysis reveals steady progress against cancer's burden, despite underestimation due to other disease advancements. Researchers measured years of life lost to cancer and found increased longevity offsetting progress.
Researchers at the University of Leicester successfully used Vemurafenib, a BRAF inhibitor approved for melanoma, to clear malignant cells from a patient's blood and achieve complete clinical recovery. The study demonstrates the potential for repurposing existing cancer treatments for rare types of leukemia.
Researchers have developed a novel DNA-barcoded antibody sensing approach to analyze hundreds of cancer-related protein markers from miniscule patient samples. This technology enables comprehensive analysis of protein expression patterns in single cells, revealing significant differences between tumors and predicting treatment response.
A comprehensive genetic study of multiple myeloma has identified subpopulations of cancer cells with different mutations within the same tumor. This discovery could impact treatment strategies and patient outcomes.
Researchers found that metformin inhibits mTOR pathway, which supports cancer growth, rather than activating AMPK. Metformin may still be useful for cancer treatment, but clinicians should use caution when interpreting data.
A USC study has identified a viral microRNA cluster responsible for causing Kaposi's sarcoma, the most common cancer among HIV-infected people. The cluster targets key cellular pathways associated with cancer development, offering potential targets for new therapeutics.
Researchers at Johns Hopkins Medicine have identified a small molecule compound called BMH-21 that targets and disrupts a key pathway in cancer cells, preventing their growth. By shutting down the RNA Polymerase pathway, BMH-21 prevents mutant cancer genes from communicating with cells and replicating.
A new study suggests that autophagy plays a key role in determining the fate of cancer cells when treated with anti-cancer drugs. Cells with high levels of autophagy were more susceptible to death from certain drugs, while those with low levels of autophagy were more resistant.
Perphenazine, a 50-year-old antipsychotic medication, has been found to actively combat cells of difficult-to-treat acute lymphoblastic leukemia (ALL) by turning on the cancer-suppressing enzyme PP2A.
Researchers have discovered that a cancer drug can protect the insulin-producing cells in the pancreas and prevent the development of type 1 diabetes in mice. The medication works by reducing sterile inflammation and delaying cell destruction. This finding is a step towards developing a preventive treatment for type 1 diabetes.
Researchers at Case Comprehensive Cancer Center have identified a microRNA biomarker, miR-181a, that predicts treatment response in ovarian cancer. Elevated levels of miR-181a are associated with chemotherapy resistance and disease progression.
Research at the University of North Carolina found that patients with higher co-payments were 70% more likely to stop taking their cancer treatment and 42% more likely to skip doses. The cost of many new pharmaceuticals can exceed $100,000 per year.
Researchers found that mutations in phosphatases lead to dysfunction of regulatory proteins that keep the oncogene in check, causing it to stay activated and promote cancer growth. This discovery suggests a new target for drugs to treat head and neck tumors and other cancers.
Researchers at North Carolina State University developed nanoparticles that deliver two different cancer-killing drugs to separate parts of the cell. The technique, tested on laboratory mice, resulted in significant tumor reduction compared to conventional treatments.
Researchers have identified a way to effectively target the beta3-integrin protein, which has been at the center of cancer drug design for 20 years. The new approach shows promise in inhibiting tumor growth and angiogenesis in mice.
Researchers analyzed nearly 20,000 people with severe psychiatric illness, finding that 30% engaged in binge drinking, 75% were regular smokers, and 50% used marijuana regularly. These findings are concerning because individuals with severe mental illness tend to die younger due to health problems caused by chronic substance use.
Researchers have identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets, suggesting that these tumors may be sensitive to MEK inhibitors. The findings could provide a new treatment option for patients with hard-to-treat melanomas.
Researchers at the University of Maryland School of Medicine found that both real and sham acupuncture reduce hot flashes and other symptoms in breast cancer patients taking an aromatase inhibitor. The study suggests that acupuncture may be a reasonable alternative to drug therapy with fewer side effects.
A new Northwestern Medicine study reveals that leading National Cancer Institute-designated comprehensive cancer centers do not consistently identify and inform patients about their fertility risks or refer them to specialists. Fertility navigators are crucial in bridging the gap between oncology and fertility, but only a third of thes...
A new radiotherapy technique uses a computer-controlled table to deliver high doses of radiation to tumors quickly and precisely, while sparing vulnerable organs. Researchers found that this method can substantially reduce the amount of radiation delivered to healthy tissue in patients with various types of cancer.
The Ben & Catherine Ivy Foundation awarded a $3 million grant to TGen, Nemucore Medical Innovations Inc., and Barrow Neurological Institute to develop targeted therapies for glioblastoma. The collaboration aims to create personalized medicine by bridging the blood-brain barrier.
A University of Colorado Cancer Center study found that ALK and ROS1 gene rearrangements, known to drive subsets of lung cancer, are also present in some colorectal cancers. This implies that drugs used to target ALK and ROS1 in lung cancer may have applications in treating a subset of colorectal cancer patients.
Researchers have found that an experimental drug targeting tumor-associated macrophages decreases glioblastoma growth and extends the survival of laboratory mice with the cancer. The treatment increases rates of programmed cell death in both the macrophages and tumor cells, leading to reduced tumor proliferation and increased survival.
A Mayo Clinic study found that endoxifen, an active metabolite of tamoxifen, is safe and shows anti-tumor activity in early-stage trials. The findings suggest a potential new treatment for estrogen-positive breast cancer patients who don't respond to standard hormonal therapies.
Researchers develop individualized systems medicine strategy to select effective cancer therapies for patients, understanding and predicting drug resistance. The approach aids in optimizing patient therapies, with promising results in treating chemoresistant adult acute myeloid leukemia (AML) patients.
A study by Dana-Farber Cancer Institute and Yale University found that moderate daily exercise can decrease joint pain in postmenopausal women taking aromatase inhibitors for breast cancer. After a year, joint pain scores decreased by 20% in the exercise group compared to 3% in the non-exercise group.
Researchers at Fox Chase Cancer Center are enrolling patients in a clinical trial of the promising drug reparixin, which targets tumors' ability to self-renew. The study aims to learn more about the effect of the drug on human breast cancer cells and its mechanisms of action.
A phase II clinical trial at the University of Texas M. D. Anderson Cancer Center showed that a combination of rituximab and pidilizumab sparked complete responses in 19 out of 29 patients with relapsed follicular lymphoma, with a response rate of 66%. The treatment had a mild side effect profile, with no grade 3 or 4 adverse events.
Researchers at Johns Hopkins Medicine found that erlotinib, a drug approved to treat lung cancer, substantially shrunk chordoma tumors in mice. The study offers new hope for chordoma patients who have exhausted traditional treatments and have limited financial incentives for pharmaceutical companies to develop new drugs.
Researchers at Dana-Farber Cancer Institute found a combination chemotherapy and targeted therapy reduced cancer recurrence in women with small, HER2-positive tumors. After 3.6 years, only 0.5% of patients experienced cancer recurrence.
Four University of Houston researchers have been elected National Academy of Inventors Fellows for their groundbreaking work in cancer treatment and materials science. The new fellows include Rathindra Bose, Dmitri Litvinov, Zhifeng Ren, and Venkat Selvamanickam, who collectively hold over 5,600 US patents.
A new study found that Herceptin plus Taxol is highly effective in treating lower-risk breast cancer patients, with a 98.7% success rate of being cancer-free for at least three years. The treatment had minimal side effects, with only 3.2% experiencing severe neuropathy.
Researchers from UCLA's Jonsson Comprehensive Cancer Center found that glioblastoma cells can temporarily eliminate gene mutations when exposed to cancer drugs, becoming drug-resistant. After the drug is removed, the tumor cells reacquire the mutation, repeating this cycle and making treatment more challenging.
Research advances demonstrate progress in cancer fight, but also stress need for increased funding to translate research into effective treatments. The report highlights three areas of progress: genomics, treatment-resistant cancers, and targeted immunotherapy.
Researchers have identified a specific genetic mutation driving Waldenstrom's Macroglobulinemia in up to 30% of patients. A new drug targeting this mutation shows promise in animal studies, offering hope for targeted treatment options.
A new gene sequencing project identifies a family of drugs that enhance oxidative stress to kill rhabdomyosarcoma tumor cells and boost chemotherapy effectiveness. The study offers hope for treating this aggressive childhood cancer, particularly for patients with recurrent disease.
Researchers at Rutgers University have developed a targeted drug delivery system that successfully treats advanced-stage ovarian cancer in mice. The treatment involves using small inhibiting RNA molecules to decrease excess CD44 protein in cancer cells while treating with anti-cancer drug paclitaxel.
Researchers identified CUX1 as a driver of tumour growth in over 3,000 cancer patients worldwide. Inactivating CUX1 leads to increased tumour progression and activation of PIK3IP1, mobilising phosphoinositide 3-kinase (PI3K) for cell growth.
A novel drug regimen featuring bortezomib has been shown to improve outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors. The regimen reduced severe acute GVHD rates and treatment-related mortality, leading to better overall survival and relapse-free survival.
A new study published in Blood journal presents a Swedish cancer drug candidate that inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The substance also kills multiple myeloma cells from cancer patients and overcomes resistance to clinically used drugs.
Researchers discovered that glioblastoma (GBM) tumor cells hide the signaling molecule targeted by therapies, adding complexity to current models of drug resistance. The findings suggest alternative approaches that could improve outcomes for cancer patients and may have significant implications for therapeutic regimens.
Researchers found that brain cancer cells temporarily lose their EGFRvIII gene mutation to evade drugs, then re-amplify it after therapy is stopped. This 'hide-and-seek' mechanism makes targeted therapies less effective, with implications for improving treatment outcomes.
Medical researchers at the University of Alberta found that one chemotherapy drug prevents another from working, making combination therapy ineffective. This discovery will guide oncologists on how to combine or avoid certain drugs, ultimately leading to better treatment options for patients.
A University of Colorado Cancer Center study validates the CARING criteria, a prognostic tool determining risk of death within a year of hospital admission. The tool uses five criteria: cancer diagnosis, chronic illness admissions, nursing home residency, ICU admission with multi-organ failure, and hospice guidelines.
Mouse models of cancer exhibit distinct DNA methylation patterns compared to human cancer samples, highlighting the need for more accurate preclinical development tools. The study provides insights into aberrant DNA methylation mechanisms in human cancer.
Selim Zilkha has pledged $5 million to the University of Southern California - Health Sciences to support a new endowed chair in Alzheimer's disease research. This gift brings his total commitment to neuroscience research at the Keck School to over $30 million.
A new class of drugs has been shown to reduce the risk of graft-vs.-host disease, a serious complication of bone marrow transplants. In a study of 61 older adults undergoing reduced-intensity bone marrow transplants, vorinostat was found to be safe and effective in preventing GVHD.
Researchers have identified a new family of proteins called glutamate intramembrane proteases, with the founding member Rce1 playing a key role in transforming healthy cells into cancer cells. This discovery could help lead to new targets for precision drug treatment and potentially develop new ways to stop Ras in its tracks in patients.
Researchers discovered epigenetic differences in colon cancer cells that render them resistant to chemotherapy drugs. The findings suggest that the inactivation of a specific gene may be responsible for this phenomenon.
A study led by Boston University School of Medicine researchers reveals that methylation signaling regulates VEGFR-2, leading to angiogenesis and tumor growth. This finding provides a promising new approach to blocking cancer growth by targeting this biochemical process.
A global survey by the European Society for Medical Oncology found that over half of the world's population lives in countries with regulations limiting access to opioid medicines for managing cancer pain. The study highlights the need for regulatory reform and education to improve access to these medicines.
Researchers have developed nanoparticles that can be delivered orally and absorbed through the digestive tract, allowing patients to take a pill instead of receiving injections. The particles are coated with antibodies that act as a key to unlock receptors found on cells lining the intestine.
Wayne State University has licensed an intellectual property portfolio claiming composition of matter and methods of use of novel analogs and derivatives of the green tea flavonoid EGCG. The collaboration, involving Q. Ping Dou and Tak-Hang Chan, aims to develop novel approaches for cancer management and related conditions.
Researchers discovered a unique leukemia-specific DNA enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), a devastating and incurable cancer. The study also reveals how a new class of promising drugs, including JQ1, halt the growth of cancer cells by targeting this enhancer element.